1
|
Puig L, Notario J, López-Ferrer A, Scheneller-Pavelescu L, Pérez B, Galache C, de la Cueva P, Carrascosa JM. Recommendations from the Spanish Academy of Dermatology and Venereology Psoriasis Working Group on the Management of Patients with Cancer and Psoriasis. Actas Dermosifiliogr 2024:S0001-7310(24)00154-6. [PMID: 38382743 DOI: 10.1016/j.ad.2024.02.013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2023] [Revised: 01/31/2024] [Accepted: 02/11/2024] [Indexed: 02/23/2024] Open
Abstract
Several studies suggest that patients with psoriasis have a higher incidence of neoplasms, especially of the skin, which could be associated with the use of therapies to treat psoriasis. Furthermore, the evidence available on the safety profile of some treatments in this context, and the management of these patients is scarce, which is why clinical practice guidelines with recommendations on the management of psoriasis in cancer patients are ambiguous. This study provides recommendations on the management and use of the therapies currently available for these patients. They are the result of a Delphi consensus reached by 45 dermatologists of the Spanish Academy of Dermatology and Venereology Psoriasis Working Group, whose goal is to help specialists in the field in their decision-making processes.
Collapse
Affiliation(s)
- L Puig
- Servicio de Dermatología, IIB Sant Pau, Hospital de la Santa Creu i Sant Pau, Barcelona, España.
| | - J Notario
- Servicio de Dermatología, Hospital Universitario de Bellvitge, Barcelona, España
| | - A López-Ferrer
- Servicio de Dermatología, Hospital de la Santa Creu i Sant Pau, Barcelona, España
| | | | - B Pérez
- Servicio de Dermatología, Hospital Morales Meseguer, Murcia, España; Facultad de Medicina, Universidad Católica San Antonio, Murcia, España
| | - C Galache
- Departamento de Dermatología, Hospital Universitario Central de Asturias, Oviedo, España
| | - P de la Cueva
- Servicio de Dermatología, Hospital Universitario Infanta Leonor, Madrid, España
| | - J M Carrascosa
- Servicio de Dermatología, Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona, IGTP, Badalona, España
| |
Collapse
|
2
|
Salgado-Boquete L, Arias-Santiago S, Belinchón-Romero I, de la Cuadra-Grande A, de la Cueva P, Gilaberte Y, Notario J, Rivera-Díaz R, Ruiz-Villaverde R, Carrascosa JM. Selection of Quality Indicators for the Certification of Psoriasis Units: The CUDERMA Project Delphi Consensus Study. Actas Dermosifiliogr 2023; 114:865-883. [PMID: 36796538 DOI: 10.1016/j.ad.2023.02.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2023] [Accepted: 02/06/2023] [Indexed: 02/17/2023] Open
Abstract
Defining quality indicators is a key strategy for ensuring the quality and standardization of health care. The CUDERMA project, an initiative of the Spanish Academy of Dermatology and Venerology (AEDV), was undertaken to define quality indicators for the certification of specialized units in dermatology; the first 2 areas selected were psoriasis and dermato-oncology. The aim of this study was to reach a consensus on what should be assessed by the indicators used to certify psoriasis units. The structured process used to do this comprised a literature review to identify potential indicators, the selection of an initial set of indicators to be evaluated by a multidisciplinary group of experts and, finally, a Delphi consensus study. A panel of 39 dermatologists evaluated the selected indicators and classified them as either "essential" or "of excellence". Consensus was finally reached on 67 indicators, which will be standardized and used to develop the certification standard for psoriasis units.
Collapse
Affiliation(s)
- L Salgado-Boquete
- Servicio de Dermatología, Complejo Hospitalario de Pontevedra, Pontevedra, Galicia, España
| | - S Arias-Santiago
- Servicio de Dermatología, Hospital Universitario Virgen de las Nieves, Granada, Andalucía, España; Facultad de Medicina, Universidad de Granada, Granada, Andalucía, España; Instituto Biosanitario de Granada (IBS), Granada, Andalucía, España.
| | - I Belinchón-Romero
- Servicio de Dermatología, Hospital General Universitario Dr. Balmis, Alicante, Comunidad Valenciana, España; Facultad de Medicina, Universidad Miguel Hernández, Alicante, Comunidad Valenciana, España; Instituto de Investigación Sanitaria y Biomédica de Alicante (ISABIAL), Alicante, Comunidad Valenciana, España
| | - A de la Cuadra-Grande
- Pharmacoeconomics & Outcomes Research Iberia (PORIB), Pozuelo de Alarcón, Madrid, España
| | - P de la Cueva
- Servicio de Dermatología, Hospital Universitario Infanta Leonor, Madrid, España
| | - Y Gilaberte
- Servicio de Dermatología, Hospital Universitario Miguel Servet, Zaragoza, Aragón, España
| | - J Notario
- Servicio de Dermatología, Hospital Universitario de Bellvitge, Barcelona, Catalunya, España
| | - R Rivera-Díaz
- Servicio de Dermatología, Hospital Universitario 12 de Octubre, Madrid, España; Facultad de Medicina, Universidad Complutense de Madrid (UCM), Madrid, España
| | - R Ruiz-Villaverde
- Servicio de Dermatología, Hospital Universitario San Cecilio, Granada, Andalucía, España; Instituto Biosanitario de Granada (IBS), Granada, Andalucía, España
| | - J M Carrascosa
- Servicio de Dermatología, Hospital Universitari Germans Trias i Pujol (HUGTiP), Barcelona, Catalunya, España; Facultad de Medicina, Universitat Autònoma de Barcelona (UAB), Barcelona, Catalunya, España; Institut d'Investigació en Ciènces de la Salut Germans Trias i Pujol (IGTP), Barcelona, Catalunya, España
| |
Collapse
|
3
|
Salgado-Boquete L, Arias-Santiago S, Belinchón-Romero I, de la Cuadra-Grande A, de la Cueva P, Gilaberte Y, Notario J, Rivera-Díaz R, Ruiz-Villaverde R, Carrascosa JM. [Translated article] Selection of Quality Indicators for the Certification of Psoriasis Units: The CUDERMA Project Delphi Consensus Study. Actas Dermosifiliogr 2023; 114:T865-T883. [PMID: 37678630 DOI: 10.1016/j.ad.2023.09.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2023] [Accepted: 02/06/2023] [Indexed: 09/09/2023] Open
Abstract
Defining quality indicators is a key strategy for ensuring the quality and standardization of health care. The CUDERMA project, an initiative of the Spanish Academy of Dermatology and Venerology (AEDV), was undertaken to define quality indicators for the certification of specialized units in dermatology; the first 2 areas selected were psoriasis and dermato-oncology. The aim of this study was to reach a consensus on what should be assessed by the indicators used to certify psoriasis units. The structured process used to do this comprised a literature review to identify potential indicators, the selection of an initial set of indicators to be evaluated by a multidisciplinary group of experts and, finally, a Delphi consensus study. A panel of 39 dermatologists evaluated the selected indicators and classified them as either "essential" or "of excellence". Consensus was finally reached on 67 indicators, which will be standardized and used to develop the certification standard for psoriasis units.
Collapse
Affiliation(s)
- L Salgado-Boquete
- Servicio de Dermatología, Complejo Hospitalario de Pontevedra, Pontevedra, Galicia, Spain
| | - S Arias-Santiago
- Servicio de Dermatología, Hospital Universitario Virgen de las Nieves, Granada, Andalucía, Spain; Facultad de Medicina, Universidad de Granada, Granada, Andalucía, Spain; Instituto Biosanitario de Granada (IBS), Granada, Andalucía, Spain.
| | - I Belinchón-Romero
- Servicio de Dermatología, Hospital General Universitario Dr. Balmis, Alicante, Comunidad Valenciana, Spain; Facultad de Medicina, Universidad Miguel Hernández, Alicante, Comunidad Valenciana, Spain; Instituto de Investigación Sanitaria y Biomédica de Alicante (ISABIAL), Alicante, Comunidad Valenciana, Spain
| | - A de la Cuadra-Grande
- Pharmacoeconomics & Outcomes Research Iberia (PORIB), Pozuelo de Alarcón, Madrid, Spain
| | - P de la Cueva
- Servicio de Dermatología, Hospital Universitario Infanta Leonor, Madrid, Spain
| | - Y Gilaberte
- Servicio de Dermatología, Hospital Universitario Miguel Servet, Zaragoza, Aragón, Spain
| | - J Notario
- Servicio de Dermatología, Hospital Universitario de Bellvitge, Barcelona, Catalunya, Spain
| | - R Rivera-Díaz
- Servicio de Dermatología, Hospital Universitario 12 de Octubre, Madrid, Spain; Facultad de Medicina, Universidad Complutense de Madrid (UCM), Madrid, Spain
| | - R Ruiz-Villaverde
- Servicio de Dermatología, Hospital Universitario San Cecilio, Granada, Andalucía, Spain; Instituto Biosanitario de Granada (IBS), Granada, Andalucía, Spain
| | - J M Carrascosa
- Servicio de Dermatología, Hospital Universitari Germans Trias i Pujol (HUGTiP), Barcelona, Catalunya, Spain; Facultad de Medicina, Universitat Autònoma de Barcelona (UAB), Barcelona, Catalunya, Spain; Institut d'Investigació en Ciènces de la Salut Germans Trias i Pujol (IGTP), Barcelona, Catalunya, Spain
| |
Collapse
|
4
|
Puig L, Carrascosa JM, Notario J. Biosimilars in the Treatment of Psoriasis: An Update. Actas Dermosifiliogr (Engl Ed) 2020; 111:809-814. [PMID: 32860750 DOI: 10.1016/j.ad.2020.03.008] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2020] [Accepted: 03/02/2020] [Indexed: 02/08/2023] Open
Affiliation(s)
- L Puig
- Servicio de Dermatología, Hospital de la Santa Creu i Sant Pau, Barcelona, España.
| | - J M Carrascosa
- Servicio de Dermatología, Hospital Universitari Germans Trias i Pujol, Badalona, España
| | - J Notario
- Servicio de Dermatología, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, España
| |
Collapse
|
5
|
Puig L, Carrascosa J, Notario J, Belinchón I. Informes de posicionamiento terapéutico: utilidad y transparencia. Actas Dermo-Sifiliográficas 2020; 111:3-6. [DOI: 10.1016/j.ad.2019.04.006] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2019] [Accepted: 04/15/2019] [Indexed: 11/28/2022] Open
|
6
|
Puig L, Carrascosa J, Notario J, Belinchón I. Treatment Appraisal Reports: Usefulness and Transparency. Actas Dermo-Sifiliográficas (English Edition) 2020. [DOI: 10.1016/j.adengl.2019.04.018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
7
|
de la Cueva Dobao P, Notario J, Ferrándiz C, López Estebaranz JL, Alarcón I, Sulleiro S, Borrás J, Daudén E, Carrascosa JM, Sánchez Carazo JL, Monte Boquet E, Puig L. Expert consensus on the persistence of biological treatments in moderate-to-severe psoriasis. J Eur Acad Dermatol Venereol 2019; 33:1214-1223. [PMID: 31037770 DOI: 10.1111/jdv.15600] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2018] [Accepted: 03/12/2019] [Indexed: 12/28/2022]
Abstract
BACKGROUND Treatment persistence is becoming a useful measure to evaluate long-term effectiveness and safety of biological therapies in real-world settings. OBJECTIVE The main objective of this study was to explore the scientific opinion of a panel of dermatologists and hospital pharmacists to reach a consensus about the impact, causes, and best strategies and interventions that might be associated with improved drug persistence in patients with psoriasis in Spain. METHODS This research was conducted using a modified Delphi method organized in two rounds and involving a panel of 90 dermatologists and 34 hospital pharmacists. A questionnaire of 70 items was developed. The items proposed to reach a consensus included topics such as definitions and measures in the treatment of psoriasis, analysis of treatment persistence, factors that may influence treatment persistence, impact of treatment persistence and economic cost of treatment. RESULTS Dermatologists reached a consensus on 77.1% of the items proposed, and hospital pharmacists reached a consensus on 71.4%. Both groups agreed that it is important to use standardized measures in the evaluation of treatment maintenance over time. Dermatologists agreed that treatment survival, persistence and retention are synonymous, but hospital pharmacists considered only treatment persistence as a valid term. In addition, panelists agreed that drug persistence is an indicator of success in the treatment of psoriasis that may be influenced by a drug's effectiveness and safety profile, as well as by patient satisfaction. They agreed that the different causes of treatment discontinuation should be considered in Kaplan-Meier analysis of treatment persistence. Moreover, treatment persistence was agreed to decrease the cost of therapy. CONCLUSION This Delphi consensus highlights the different perspectives of dermatologists and hospital pharmacists regarding the interpretation of treatment persistence, and the challenge of harmonizing the results obtained.
Collapse
Affiliation(s)
- P de la Cueva Dobao
- Department of Dermatology, Hospital Universitario Infanta Leonor, Madrid, Spain
| | - J Notario
- Department of Dermatology, Hospital Universitario de Bellvitge, Barcelona, Spain
| | - C Ferrándiz
- Department of Dermatology, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain.,Universidad Autónoma de Barcelona, Barcelona, Spain
| | - J L López Estebaranz
- Department of Dermatology, Hospital Universitario Fundación de Alcorcón, Alcorcón, Madrid, Spain
| | - I Alarcón
- Medical Affairs Department, Janssen-Cilag, Madrid, Spain
| | - S Sulleiro
- Medical Affairs Department, Janssen-Cilag, Madrid, Spain
| | - J Borrás
- Pharmacy Service, Hospital de Sagunto, Sagunto, Valencia, Spain
| | - E Daudén
- Department of Dermatology, Hospital Universitario de La Princesa, IIS-FIB, Madrid, Spain
| | - J M Carrascosa
- Department of Dermatology, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain.,Universidad Autónoma de Barcelona, Barcelona, Spain
| | - J L Sánchez Carazo
- Department of Dermatology, Hospital General Universitario de Valencia, Valencia, Spain
| | - E Monte Boquet
- Pharmacy Service, Hospital Universitario y Politécnico La Fe, Valencia, Spain
| | - L Puig
- Universidad Autónoma de Barcelona, Barcelona, Spain.,Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
| |
Collapse
|
8
|
Deza G, Notario J, Lopez-Ferrer A, Vilarrasa E, Ferran M, Del Alcazar E, Carrascosa JM, Corral M, Salleras M, Ribera M, Puig L, Pujol RM, Vidal D, Gallardo F. Initial results of ixekizumab efficacy and safety in real-world plaque psoriasis patients: a multicentre retrospective study. J Eur Acad Dermatol Venereol 2018; 33:553-559. [PMID: 30317679 DOI: 10.1111/jdv.15288] [Citation(s) in RCA: 26] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2018] [Accepted: 09/27/2018] [Indexed: 01/13/2023]
Abstract
BACKGROUND Ixekizumab (anti-IL17A) is effective as treatment for moderate-to-severe plaque psoriasis, but real-life data on effectiveness and safety are currently very limited. OBJECTIVE To evaluate the efficacy and safety of ixekizumab in a cohort of real-life plaque psoriasis patients. METHODS Retrospective chart review of 100 patients with moderate-to-severe plaque psoriasis treated with ixekizumab at seven Spanish dermatological centres. RESULTS According to the as observed analysis, the percentage of patients achieving a 75% and 90% of reduction from the baseline score of Psoriasis Area and Severity Index (PASI) was 87.5%-50.0% at week 12-16; 88.3%-58.4% at week 24 and 82.9%-58.5% at week 52, respectively. The mean ± standard deviation (SD) score of PASI at baseline was 12.9 ± 9.2, and it declined rapidly after ixekizumab administration to 1.9 ± 4.0 (P < 0.001) at week 12-16 and was maintained at 1.7 ± 4.1 and 1.8 ± 2.9 at week 24 and 52, respectively. Ixekizumab response was not affected by clinical variables like body mass index, disease duration or the presence of psoriatic arthritis. However, the bio-naive group showed significantly higher PASI 75 response rate at week 12-16 compared to patients previously exposed to biologic agents (P = 0.037). Twenty-six (26%) patients experienced adverse events (AEs) during the follow-up period, being most of them of mild-to-moderate intensity. The most common AE was local reaction at the site of injection (14/26; 53.8%). At the end of the observational period, 15 (15%) patients discontinued ixekizumab treatment due to limited clinical improvement (n = 11), adverse events (n = 3) or lost to follow-up (n = 1) within a mean ± SD time of 6.0 ± 3.9 months. CONCLUSION The present study illustrates the initial experience with ixekizumab in real-world clinical practice confirming its usefulness and safety in the management of plaque psoriasis patients.
Collapse
Affiliation(s)
- G Deza
- Department of Dermatology, Hospital del Mar-Institut Mar d'Investigacions Mèdiques, Barcelona, Spain
| | - J Notario
- Department of Dermatology, Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Spain
| | - A Lopez-Ferrer
- Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
| | - E Vilarrasa
- Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
| | - M Ferran
- Department of Dermatology, Hospital del Mar-Institut Mar d'Investigacions Mèdiques, Barcelona, Spain
| | - E Del Alcazar
- Department of Dermatology, Hospital Germans Trias i Pujol, Badalona, Spain
| | - J M Carrascosa
- Department of Dermatology, Hospital Germans Trias i Pujol, Badalona, Spain
| | - M Corral
- Department of Dermatology, Hospital Universitari Sagrat Cor, Barcelona, Spain
| | - M Salleras
- Department of Dermatology, Hospital Universitari Sagrat Cor, Barcelona, Spain
| | - M Ribera
- Department of Dermatology, Hospital Parc Taulí, Sabadell, Spain
| | - L Puig
- Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
| | - R M Pujol
- Department of Dermatology, Hospital del Mar-Institut Mar d'Investigacions Mèdiques, Barcelona, Spain
| | - D Vidal
- Department of Dermatology, Hospital Moisès Broggi, Sant Joan Despí, Spain
| | - F Gallardo
- Department of Dermatology, Hospital del Mar-Institut Mar d'Investigacions Mèdiques, Barcelona, Spain
| |
Collapse
|
9
|
Llamas-Velasco M, de la Cueva P, Notario J, Martínez-Pilar L, Martorell A, Moreno-Ramírez D. Moderate Psoriasis: A Proposed Definition. ACTA ACUST UNITED AC 2017. [DOI: 10.1016/j.adengl.2017.10.003] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
10
|
Llamas-Velasco M, de la Cueva P, Notario J, Martínez-Pilar L, Martorell A, Moreno-Ramírez D. Moderate Psoriasis: A Proposed Definition. Actas Dermosifiliogr 2017; 108:911-917. [PMID: 28823420 DOI: 10.1016/j.ad.2017.07.002] [Citation(s) in RCA: 32] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2017] [Revised: 06/17/2017] [Accepted: 07/02/2017] [Indexed: 12/19/2022] Open
Abstract
INTRODUCTION The Psoriasis Area Severity Index (PASI) is the most widely used scale for assessing the severity of psoriasis and for therapeutic decision making. On the basis of the PASI score, patients have been stratified into 2 groups: mild disease and moderate-to-severe disease. OBJECTIVE To draft a proposal for the definition and characterization of moderate psoriasis based on PASI and Dermatology Life Quality Index (DLQI) scores. MATERIAL AND METHODS A group of 6 dermatologists with experience in the treatment of psoriasis undertook a critical review of the literature and a discussion of cases to draft a proposal. RESULTS In order of priority, PASI, DLQI, and body surface area (BSA) are the parameters to be used in daily practice to classify psoriasis as mild, moderate, or severe. Severity should be assessed on the basis of a combined evaluation and interpretation of the PASI and DLQI. And 3, PASI and DLQI should carry equal weight in the determination of disease severity. On this basis, psoriasis severity was defined using the following criteria: mild, PASI<7 and DLQI<7; moderate, PASI=7-15 and DLQI=5-15 (classified as severe when difficult-to-treat sites are affected or when there is a significant psychosocial impact); severe, PASI >15, independently of the DLQI score. CONCLUSIONS A more precise classification of psoriasis according to disease severity will improve the risk-benefit assessment essential to therapeutic decision making in these patients.
Collapse
Affiliation(s)
- M Llamas-Velasco
- Departamento Dermatología, Hospital Universitario la Princesa, Instituto de Investigación Sanitaria la Princesa (IIS-IP), Madrid, España.
| | - P de la Cueva
- Departamento Dermatología, Hospital Universitario Infanta Leonor, Madrid, España
| | - J Notario
- Departamento Dermatología, Hospital de Bellvitge, Barcelona, España
| | - L Martínez-Pilar
- Departamento Dermatología, Hospital Regional Universitario Carlos Haya, Málaga, España
| | - A Martorell
- Departamento Dermatología, Hospital de Manises, Valencia, España
| | - D Moreno-Ramírez
- Departamento Dermatología, Hospital Universitario Virgen de la Macarena, Sevilla, España
| |
Collapse
|
11
|
Carrascosa JM, de la Cueva P, Herranz P, Labandeira J, Notario J. Perception of psoriasis treatment in the outpatient setting: survey of patients and their prescribing physicians. J DERMATOL TREAT 2016; 28:188-199. [PMID: 27569650 DOI: 10.1080/09546634.2016.1230174] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
BACKGROUND Patients' perception of disease management can influence compliance to treatment and thus affect outcome. OBJECTIVE To survey patients and physicians on their perceptions of biologic therapy for treating psoriasis in an outpatient setting. METHODS The subjective impact of intravenous treatment of severe psoriasis on patients and physicians in the outpatient setting was determined via two surveys. RESULTS Between September and November 2014, 24 dermatologists and 90 patients were surveyed. Treatment with biologic agents in the outpatient setting was associated with a high level of patient satisfaction: 93.3% of patients considered their psoriasis well controlled and 46.1% reported complete control. Patients highly valued the feeling of greater disease control (72.2%), regular follow-up (66.7%) and rapid improvement of psoriasis (58.9%) when attending an outpatient setting. Other positive aspects of outpatient treatment were control of other health issues and perceived improvements in quality of life (QoL). Outpatient attendance was high; with 90% of patients keeping scheduled appointments and 79.2% of physicians acknowledged that they were able to monitor their patients' condition more closely. CONCLUSION Administration of treatment in an outpatient setting may provide a feeling of improved QoL and disease control.
Collapse
Affiliation(s)
- J M Carrascosa
- a Dermatology Department , Hospital Universitari Germans Trias i Pujol , Badalona , Spain
| | - P de la Cueva
- b Dermatology Department , Hospital Universitario Infanta Leonor , Madrid , Spain
| | - P Herranz
- c Dermatology Department , Hospital Universitario La Paz , Madrid , Spain
| | - J Labandeira
- d Dermatology Department , Complejo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela , Spain
| | - J Notario
- e Dermatology Department , Hospital Universitario de Bellvitge , Barcelona , Spain
| |
Collapse
|
12
|
Colls M, Padulles N, Padullés A, Notario J, Bas J, Sanmarti N, Colom H. PKP-012 Body surface area, cigarrete smoking and infliximab response in patients with psoriasi. Eur J Hosp Pharm 2016. [DOI: 10.1136/ejhpharm-2016-000875.415] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022] Open
|
13
|
Carrascosa J, Notario J. Supervivencia en terapia biológica. ¿Sabemos a qué nos referimos? ¿ Podemos usarla? Actas Dermo-Sifiliográficas 2014; 105:729-33. [DOI: 10.1016/j.ad.2014.04.004] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2014] [Revised: 04/15/2014] [Accepted: 04/15/2014] [Indexed: 02/08/2023] Open
|
14
|
Carrascosa J, Notario J. Drug Survival in Biologic Therapy. Do We Know What it Means? Can We Calculate it? Actas Dermo-Sifiliográficas (English Edition) 2014. [DOI: 10.1016/j.adengl.2014.04.022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
15
|
Martin-Ezquerra G, Masferrer E, Masferrer-Niubò M, Ferran M, Sánchez-Regaña M, Collgros H, Bordas X, Notario J, Alsina M, Gil I, Izquierdo N, Aparicio G, Mollet J, Garcia-Patos V, Pujol R. Use of biological treatments in patients with hidradenitis suppurativa. J Eur Acad Dermatol Venereol 2014; 29:56-60. [DOI: 10.1111/jdv.12438] [Citation(s) in RCA: 35] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/04/2013] [Accepted: 01/31/2014] [Indexed: 01/28/2023]
Affiliation(s)
| | - E. Masferrer
- Dermatology Department; Hospital del Mar; Barcelona Spain
| | - M. Masferrer-Niubò
- Mathematic Department; Universidad Nacional de Educación a Distancia UNED; Barcelona Spain
| | - M. Ferran
- Dermatology Department; Hospital del Mar; Barcelona Spain
| | | | - H. Collgros
- Dermatology Department; Hospital Sagrat Cor; Barcelona Spain
| | - X. Bordas
- Dermatology Department; Hospital de Bellvitge; Barcelona Spain
| | - J. Notario
- Dermatology Department; Hospital de Bellvitge; Barcelona Spain
| | - M. Alsina
- Dermatology Department; Hospital Clínic; Barcelona Spain
| | - I. Gil
- Dermatology Department; Hospital Sant Joan de Reus; Reus Spain
| | - N. Izquierdo
- Dermatology Department; Hospital Son Espases; Palma de Mallorca Spain
| | - G. Aparicio
- Dermatology Department; Hospital de la Vall d ‘Hebron; Barcelona Spain
| | - J. Mollet
- Dermatology Department; Hospital de la Vall d ‘Hebron; Barcelona Spain
| | - V. Garcia-Patos
- Dermatology Department; Hospital de la Vall d ‘Hebron; Barcelona Spain
| | - R.M. Pujol
- Dermatology Department; Hospital del Mar; Barcelona Spain
| |
Collapse
|
16
|
Puig L, Carrascosa J, Carretero G, de la Cueva P, Lafuente-Urrez R, Belinchón I, Sánchez-Regaña M, García-Bustínduy M, Ribera M, Alsina M, Ferrándiz C, Fonseca E, García-Patos V, Herrera E, López-Estebaranz J, Marrón S, Moreno J, Notario J, Rivera R, Rodriguez-Cerdeira C, Romero A, Ruiz-Villaverde R, Taberner R, Vidal D. Spanish Evidence-Based Guidelines on the Treatment of Psoriasis With Biologic Agents, 2013. Part 1: On Efficacy and Choice of Treatment. ACTA ACUST UNITED AC 2013; 104:694-709. [DOI: 10.1016/j.adengl.2013.04.013] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2013] [Accepted: 04/02/2013] [Indexed: 02/08/2023]
|
17
|
Puig L, Carrascosa J, Carretero G, de la Cueva P, Lafuente-Urrez R, Belinchón I, Sánchez-Regaña M, García-Bustínduy M, Ribera M, Alsina M, Ferrándiz C, Fonseca E, García-Patos V, Herrera E, Estebaranz JL, Marrón S, Moreno J, Notario J, Rivera R, Rodriguez-Cerdeira C, Romero A, Ruiz-Villaverde R, Taberner R, Vidal D. Directrices españolas basadas en la evidencia para el tratamiento de la psoriasis con agentes biológicos, 2013. I. Consideraciones de eficacia y selección del tratamiento. Actas Dermo-Sifiliográficas 2013. [DOI: 10.1016/j.ad.2013.04.003] [Citation(s) in RCA: 91] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022] Open
|
18
|
Carretero G, Ribera M, Belinchón I, Carrascosa J, Puig L, Ferrandiz C, Dehesa L, Vidal D, Peral F, Jorquera E, Gonzalez-Quesada A, Muñoz C, Notario J, Vanaclocha F, Moreno J. Acitretina: guía de uso en psoriasis. Actas Dermo-Sifiliográficas 2013. [DOI: 10.1016/j.ad.2013.01.003] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022] Open
|
19
|
Carretero G, Ribera M, Belinchón I, Carrascosa JM, Puig L, Ferrandiz C, Dehesa L, Vidal D, Peral F, Jorquera E, González-Quesada A, Muñoz C, Notario J, Vanaclocha F, Moreno JC. Guidelines for the use of acitretin in psoriasis. Psoriasis Group of the Spanish Academy of Dermatology and Venereology. Actas Dermosifiliogr 2013; 104:598-616. [PMID: 23891453 DOI: 10.1016/j.adengl.2013.01.001] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2012] [Accepted: 01/20/2013] [Indexed: 02/01/2023] Open
Abstract
Phototherapy, classic systemic treatments (methotrexate, acitretin, and ciclosporin), and biologic agents (etanercept, infliximab, adalimumab, and ustekinumab) constitute a broad therapeutic arsenal that increases the likelihood of achieving control of severe and extensive disease in patients with psoriasis. Acitretin continues to be a very valuable tool in both monotherapy, in which it is combined with other systemic treatments (classic or biologic), and in sequential therapy. Thanks to its lack of a direct immunosuppressive effect and its ability to achieve a long-term response, acitretin has an important role in the treatment of psoriasis, although this has not always been acknowledged in relevant treatment guidelines. We present consensus guidelines for the use of acitretin in psoriasis drawn up by the Psoriasis Group of the Spanish Academy of Dermatology and Venereology. These guidelines provide a detailed account of acitretin, including pharmacological properties, indications and contraindications, adverse effects, and factors that should be taken into account to enhance the safe use of this drug. They also propose treatment strategies for use in routine clinical practice. The overall aim of these guidelines is to define the criteria for the use and management of acetretin in psoriasis.
Collapse
Affiliation(s)
- G Carretero
- Grupo de Psoriasis de la Academia Española de Dermatología y Venereología, Spain.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Notario J, Bordas X. Manejo práctico de ustekinumab en la psoriasis moderada-grave. Actas Dermo-Sifiliográficas 2012. [DOI: 10.1016/s0001-7310(12)70009-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
|
21
|
Marcoval J, Notario J, Martín-Sala S, Figueras I. Pigmentation of the Fungiform Papillae of the Tongue: A Report of 2 Cases. Actas Dermo-Sifiliográficas (English Edition) 2011. [DOI: 10.1016/j.adengl.2011.11.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022] Open
|
22
|
Abstract
The aim of our study was to determine the influence of several types of liposomes with a different lipid composition on the percutaneous absorption of one conventional sun filter with a lipophilic character (ethyl hexyl methoxycinnamate) using both in vitro and in vivo methodologies. Three different liposomes were prepared with unsaturated and saturated phosphatidylcholine (PC, HPC), and with a wool lipid mixture (IWL) with a composition similar to that of the stratum corneum lipids. Results showed that the liquid crystalline state associated with PC liposomes plays a key role in enhancing skin penetration. when liposomes with a composition and structural organization similar to that of the stratum corneum lipids (HPC and IWL) are used, the skin penetration is retarded, suggesting a certain reinforcement of the stratum corneum barrier. These two types of liposomes could be regarded as alternatives to conventional oil/water emulsions in the formulations of lipidic sun filters. Finally, an acceptable correlation was obtained using both in vitro and in vivo methodologies to evaluate the corresponding skin absorption profile.
Collapse
Affiliation(s)
- E Ramón
- IIQAB (CSIC), Jordi Girona 18-26, 08034 Barcelona, Spain.
| | | | | | | | | | | | | |
Collapse
|
23
|
|
24
|
|
25
|
|
26
|
Affiliation(s)
- J Graells
- Department of Dermatology, Ciutat Sanitària i Universitària de Bellvitge, Barcelona, Spain
| | | | | | | | | |
Collapse
|
27
|
Badell A, Servitje O, Graells J, Curcó N, Notario J, Peyrí J. Salivary gland lymphoplasmacytoid lymphoma with nodular cutaneous amyloid deposition and lambda chain paraproteinaemia. Br J Dermatol 1996; 135:327-9. [PMID: 8881687] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
We report the case of an 83-year-old woman who developed a lymphoplasmacytoid lymphoma of the salivary glands with extension to the skin of the cheeks and laterocervical area. The most remarkable feature was the massive amyloid deposition that gave the cutaneous lesions a distinctive clinical appearance, similar to that observed in cases of nodular cutaneous amyloidosis. An IgM-lambda paraprotein was also detected in the serum.
Collapse
Affiliation(s)
- A Badell
- Department of Dermatology, Hospital Prínceps d'Espanya Ciutat Sanitària i Universitària de Bellvitge, Barcelona, Spain
| | | | | | | | | | | |
Collapse
|
28
|
Graells J, Marcoval M, Badell A, Notario J, Fulladosa X. Muir-Torré syndrome in a patient with acquired immunodeficiency syndrome. Br J Dermatol 1996; 135:159-61. [PMID: 8776396] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
|
29
|
|
30
|
|